MAMs are not organs in the conventional sense but specialized zones of close physical contact between the endoplasmic reticulum, the cell’s protein and lipid factory, and mitochondria, its power plants. The two membranes are held roughly 10 to 25 nanometers apart by protein tethers, including the mitofusin 2 bridge, the voltage-dependent anion channel VDAC1 on the mitochondrial outer membrane paired with the inositol trisphosphate receptor IP3R on the ER via the chaperone GRP75, and additional connectors such as PTPIP51, VAPB and ATAD3A. This architecture is far more than scaffolding. At these contact points the cell exchanges calcium from ER stores into mitochondria, synthesizes and shuttles phospholipids, coordinates mitochondrial fission through the dynamin-related protein Drp1, and monitors mitochondrial quality through mitophagy pathways involving PINK1 and Parkin. In cardiomyocytes, which beat billions of times over a lifetime and depend on relentless ATP production, the integrity of these contacts is a matter of survival.

The review’s central mechanistic claim is that during ischemia and especially reperfusion, MAMs become the staging ground for a signaling cascade that runs from ER stress to mitochondrial catastrophe. The key player is PERK, the protein kinase R-like endoplasmic reticulum kinase, an ER stress sensor that sits within MAMs. When reperfusion floods the cell with calcium and misfolded proteins accumulate, PERK activates and phosphorylates eukaryotic initiation factor 2α, triggering the unfolded protein response and the transcription factor ATF4, which in turn induces the pro-death protein CHOP. This PERK-MAM axis drives mitochondrial reactive oxygen species production, and the resulting oxidative burden pushes cardiomyocytes toward ferroptosis, an iron-dependent form of regulated cell death defined by the catastrophic peroxidation of polyunsaturated fatty acids in cellular membranes.

Ferroptosis is biochemically distinct from apoptosis and necrosis, and the review places MAMs at the heart of its lipid supply chain. The phospholipid remodeling that generates vulnerable peroxidation substrates depends on enzymes such as acyl-CoA synthetase 4, or ACSL4, and lipoxygenases including ALOX15, which incorporate polyunsaturated fatty acids like arachidonic acid into membrane phosphatidylethanolamine. Critically, the synthesis of phosphatidylethanolamine itself occurs at MAMs, where phosphatidylserine generated in the ER is transferred to mitochondria and decarboxylated by phosphatidylserine decarboxylase. In other words, the very contact sites that manufacture the cell’s membranes also determine whether those membranes become fuel for ferroptotic destruction. When the antioxidant defense system fails, particularly glutathione peroxidase 4, or GPX4, which normally repairs lipid hydroperoxides, the accumulated peroxides rupture membranes and kill the cell.

The calcium dimension adds another layer of lethality. Reperfusion delivers a surge of calcium that overloads mitochondria through the MAM-adjacent calcium uniporter MCU, promoting opening of the mitochondrial permeability transition pore, collapse of the membrane potential and further reactive oxygen species generation. Excessive MAM tethering, the review notes, can worsen this calcium overload, while excessive detachment disrupts energy metabolism and mitochondrial dynamics. The therapeutic window therefore appears to be narrow and precisely regulated: a healthy heart needs MAMs neither too tight nor too loose. Disruption of this balance also impairs mitochondrial fission and fusion, and the review highlights roles for FUNDC1-mediated mitophagy and sirtuins such as SIRT1 and SIRT3 in maintaining mitochondrial quality at these contact sites.

Perhaps the most clinically ambitious section of the review connects acute reperfusion injury to chronic ventricular remodeling, the slow process of scarring, dilatation and heart failure that follows myocardial infarction. The authors argue that MAM damage is not a one-off event but a continuous pathological thread. Persistent MAM dysfunction in surviving cardiomyocytes, cardiac fibroblasts and cardiac microvascular endothelial cells sustains lipid peroxidation, inflammatory signaling through pathways such as TLR4, NF-κB and the JNK and MAPK cascades, and maladaptive fibroblast activation. Ferroptotic death of cardiomyocytes releases damage signals and iron that further fuel fibrosis, while endothelial MAM dysfunction impairs microvascular recovery. By classifying the experimental evidence into cardiac ischemia-reperfusion models, permanent infarction models, post-infarction remodeling models and non-cardiac mechanistic systems, the authors attempt to make clear which findings speak to acute injury and which to long-term remodeling.

On the therapeutic front, the review surveys an unusually broad arsenal organized around what it calls the MAMs-lipid metabolism-ferroptosis axis. Small-molecule ferroptosis inhibitors such as ferrostatin-1 and liproxstatin-1, which intercept lipid radicals, have shown cardioprotective effects in experimental reperfusion models, as have mitochondria-targeted antioxidants like Mitoquinone, or MitoQ. Modulators of ER-mitochondrial tethering, including agents that stabilize the sigma-1 receptor at MAMs, represent a more structurally targeted approach. Natural active ingredients, including thymoquinone from black seed oil and various traditional Chinese medicine compounds, are reported to act through antioxidant, anti-ferroptotic and MAM-stabilizing mechanisms, often by activating the Nrf2 antioxidant pathway or preserving GPX4 activity. The review also discusses gene therapy strategies aimed at restoring mitofusin 2 expression or silencing ACSL4, and emerging nano-delivery systems designed to carry ferroptosis inhibitors specifically to the ischemic myocardium.

The translational logic is compelling because it addresses a gap that existing therapies cannot close. Reperfusion strategies such as primary percutaneous coronary intervention save lives but do nothing to prevent the downstream cell death programs they inadvertently ignite, and no approved drug currently protects the human heart against MIRI. A therapy that simultaneously dampens acute ferroptotic death during reperfusion and limits the chronic remodeling that leads to heart failure would be genuinely transformative, and the MAM platform offers a mechanistic rationale for why a single intervention might achieve both. The authors frame their work as providing a systematic theoretical basis and translational direction for such dual-benefit myocardial protective therapies.

Important caveats remain, and the review is candid about them. As a narrative review based on literature in PubMed and Web of Science through March 2026, it did not apply formal systematic screening, and much of the evidence it synthesizes comes from cell culture and animal models whose fidelity to human reperfusion injury varies. The precise dose-response relationship between MAM tethering and injury, the identity of the best drugable nodes in the PERK-mtROS-ferroptosis cascade, and the safety of chronically altering organelle contacts in a beating heart all require direct experimental testing. Biomarkers that would allow clinicians to measure MAM dysfunction or ferroptotic burden in patients are still lacking. Yet the sheer convergence of calcium biology, lipid chemistry and cell death signaling at these nanometer-scale contact points makes them one of the most intriguing targets in cardiovascular medicine, and this review offers the clearest map yet of how a structural curiosity of cell biology could become the key to protecting the reperfused heart.

Subject of Research: The role of mitochondria-associated endoplasmic reticulum membranes in myocardial ischemia-reperfusion injury, lipid metabolism and ferroptosis

Article Title: Mitochondria-associated endoplasmic reticulum membranes in myocardial ischemia-reperfusion injury: integrating lipid metabolism and ferroptosis

Article References: Guan, X., Cheng, H., Li, Z., Li, J., Wen, N., & Wang, L. (2026). Mitochondria-associated endoplasmic reticulum membranes in myocardial ischemia-reperfusion injury: integrating lipid metabolism and ferroptosis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09052-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09052-7

Keywords: MAMs, myocardial ischemia-reperfusion injury, ferroptosis, lipid metabolism, mitochondria, endoplasmic reticulum, ventricular remodeling, PERK, reactive oxygen species, cardioprotection, GPX4, therapeutic targets

The physiological anchor of the review is the recognition that heart failure is, at its core, a disease of disturbed mechanics. Changes in myocardial stiffness, fiber architecture, wall stress distribution, and chamber geometry drive the maladaptive remodeling that precedes irreversible decline. The authors emphasize that conventional metrics such as ejection fraction and chamber dimensions often miss the regional biomechanical abnormalities that determine therapeutic response. This is particularly true for heart failure with preserved ejection fraction, a phenotype increasingly understood as a disorder of diastolic dysfunction, microvascular impairment, and ventricular–vascular uncoupling rather than simple pump failure. At the molecular level, dysregulation of calcium-handling proteins including SERCA2a, the ryanodine receptor RyR2, and the sodium–calcium exchanger produces distinct cellular signatures in reduced- versus preserved-ejection-fraction disease, linking subcellular dysfunction to the macroscopic stiffness and impaired relaxation that clinicians measure at the bedside.

Finite-element modeling is the computational backbone of this convergence. By combining imaging-derived geometry with constitutive laws describing myocardial tissue behavior and physiologically realistic boundary conditions, these models can quantify regional stress and strain that no global clinical index can capture. The review illustrates the power of this approach through bioprosthetic heart valves, whose durability limits remain a major clinical problem. Under cyclic loading, valve leaflets undergo progressive geometric remodeling: after roughly 50 million cycles, equivalent to about two years of in vivo function, leaflets show permanent deformation concentrated in the central belly region, accompanied by collagen redistribution rather than outright fiber rupture. Time-dependent finite-element frameworks that iteratively update material parameters and remesh geometry across loading cycles can now reproduce this staged evolution from early remodeling to stress redistribution and eventual failure.

Collagen architecture emerges as a decisive variable in these simulations. Comparative finite-element studies incorporating isotropic fiber distributions, exogenously crosslinked bovine pericardial architectures, and native porcine aortic valve fiber architectures reveal striking differences in deformation behavior. Valves with isotropic or pericardial fiber arrangements deform relatively uniformly, with maximum in-plane Green–Lagrange strains of approximately 0.2, whereas valves carrying native fiber alignment display pronounced spatial heterogeneity, particularly within the leaflet belly. The modeling also shows that stress concentrations localize precisely where calcification and structural failure are observed experimentally, providing compelling evidence for mechanobiological coupling between cyclic stress exposure, collagen organization, and mineral deposition. For heart failure care, the relevance is indirect but important: these valve studies supply validated methods for quantifying how loading conditions, device–tissue interactions, and ventricular–vascular coupling shape remodeling trajectories.

Computational predictions, however, are only as credible as their experimental validation, and this is where three-dimensional printing enters the pipeline. What began as static anatomical replication from computed tomography datasets has matured into functional phantoms that reproduce both anatomy and mechanical behavior. Multimaterial printing technologies such as PolyJet can combine compliant soft-tissue regions with rigid calcified components in a single model, a capability the review highlights as particularly valuable for replicating aortic stenosis. When such patient-specific phantoms are coupled to pulsatile flow loops, they reproduce echocardiographic features and hemodynamic profiles of severe disease, with experimental measurements of transvalvular gradients and effective orifice area closely matching patient Doppler data. Fluid–structure interaction simulations based on the immersed boundary method, validated against pulse-duplicator experiments, show good qualitative agreement in leaflet kinematics, with residual discrepancies attributed to geometric variability between leaflets, differences in collagen architecture, and turbulent flow effects at physiological Reynolds numbers on the order of 20,000.

The clinical footprint of printed models already extends well beyond the bench. In pediatric and congenital heart disease, where complex spatial relationships among chambers, great vessels, and airways defy two-dimensional imaging, printed models have improved surgical strategy selection, interdisciplinary communication, and trainee education. In structural heart interventions, patient-specific models allow bench-top rehearsal of transcatheter valve deployment, atrial septal defect closure, and ventricular assist device placement, with quantitative prediction of paravalvular leak demonstrated using tissue-mimicking aortic root phantoms and biomechanically informed parameters such as the maximum bulge index. For adults with congenital heart disease complicated by heart failure, printed models have visualized systemic right ventricles, Fontan pathways, and surgically constructed baffles, directly supporting planning for advanced therapies including ventricular assist device implantation. The review stresses a critical caveat: geometric fidelity alone is insufficient, and mechanical fidelity must be characterized under use-specific loading conditions for a printed model to serve as a meaningful biomechanical surrogate.

Artificial intelligence completes the triad by extracting clinically actionable patterns from high-dimensional data. The review surveys a hierarchy from machine learning to deep learning, noting that rigorous separation of training, validation, and testing datasets is essential to avoid information leakage and inflated performance claims. Concrete applications are already impressive: an AI-enabled electronic stethoscope detected left-sided valve disease from heart sounds with area under the receiver operating characteristic curve values of 0.76 for aortic stenosis, 0.79 for mitral regurgitation, and 0.85 for composite left-sided disease, supporting point-of-care screening. Automated software quantifies aortic annular dimensions dynamically across the cardiac cycle, and the fully automated 4TAVR pipeline performs segmentation, landmark identification, measurement extraction, and report generation from computed tomography without any user interaction. Machine learning models predicting in-hospital mortality after transcatheter aortic valve replacement achieved an area under the curve of 0.92, with logistic regression outperforming more complex architectures. Natural language processing has exposed discrepancies between quantitative measurements and narrative conclusions in echocardiographic reports, while acoustic analysis of ventricular assist device sounds identifies complications such as significant regurgitation through harmonic amplitude and rotational speed features.

The review’s most sobering contribution is its candid assessment of evidence maturity, which it finds strikingly heterogeneous across the three technologies. Finite-element approaches remain predominantly validated in retrospective or simulation-based studies with limited prospective clinical testing, earning a low-to-moderate clinical readiness rating. Three-dimensional printed phantoms are widely used for in vitro testing and procedural rehearsal, yet direct evidence linking their use to improved patient outcomes is minimal, yielding the lowest readiness score. Artificial intelligence has achieved the broadest clinical integration, particularly in imaging and risk stratification, but most models rest on retrospective datasets without robust external validation. Strikingly, the authors identified no prospective studies directly linking patient-specific finite-element descriptors or phantom testing to hard endpoints such as all-cause mortality or heart failure hospitalization. They also caution that pooling accuracy metrics across these approaches is inappropriate because endpoints, datasets, and validation standards differ so substantially.

To close this gap, the review proposes a concrete research agenda built around candidate mechanical descriptors for heart failure phenotyping, including peak regional von Mises stress, end-systolic principal strain, strain heterogeneity index, transmural strain gradient, myocardial work density, annular displacement, and peak leaflet stress. Each descriptor is paired with a minimum validation pathway running from bench calibration through phantom testing to retrospective association and, ultimately, prospective outcome-linked trials. The authors acknowledge that finite-element outputs are sensitive to imaging quality, segmentation, constitutive assumptions, boundary conditions, and mesh resolution, and that harmonized reporting standards are prerequisites for multicenter comparison. Ethical considerations, including data governance, transparency, and algorithmic bias, must be resolved in parallel to earn regulatory and clinical trust.

The vision that emerges is not of any single technology replacing clinical judgment, but of an integrated ecosystem in which computational mechanics, physical validation, and data-driven prediction are jointly optimized for each patient. Imaging feeds patient-specific finite-element models; those models guide the fabrication of functional phantoms that experimentally confirm predicted stresses and flows; machine learning accelerates segmentation, builds surrogate models, and maps heterogeneous phenotypes such as preserved-ejection-fraction subtypes onto mechanistic descriptors. The authors conclude that these technologies are best viewed today as complementary components of a developing translational ecosystem rather than standalone clinical tools, with their greatest impact contingent on rigorous validation, standardized reporting, and heart-failure-specific clinical targeting. If prospective multicenter trials confirm the framework’s promise, the digital–physical twin could shift heart failure management from reactive measurement of global indices toward predictive, personalized, and mechanistically grounded care.

Subject of Research: Integration of finite-element modeling, 3D printing, and artificial intelligence for heart failure diagnosis and prognosis

Article Title: Mechanical‐medical convergence in heart failure: Artificial intelligence, finite‐element modeling, and 3D printing for diagnosis and prognosis

Article References: Sabrina, Q. N. E., Zobaer Shah, Q. M., Sohela, Q. N. E., Mousum, M. M. H., Chisty, M. M. U., & Shah, Q. M. A. (2026). Mechanical‐medical convergence in heart failure: Artificial intelligence, finite‐element modeling, and 3D printing for diagnosis and prognosis. Bioengineering & Translational Medicine, 11(5), Article e70156. https://doi.org/10.1002/btm2.70156

Image Credits: AI Generated

DOI: 10.1002/btm2.70156

Keywords: heart failure, finite-element modeling, 3D printing, artificial intelligence, digital twin, cardiac biomechanics, bioprosthetic heart valves, ventricular remodeling, machine learning, patient-specific modeling, transcatheter valve replacement, precision medicine

The stakes of this question are enormous. Ischemic heart disease remains the leading cause of death worldwide, and while timely reperfusion of a blocked coronary artery has dramatically reduced mortality, myocardial necrosis is often unavoidable. The surviving ventricle then embarks on a remodeling process—chamber dilation, wall thinning, scar formation—that can end in congestive heart failure, a condition whose mortality rivals that of many common cancers. Because most heart attack patients are older than sixty, while the mice used in preclinical studies are typically around twelve weeks old, the age mismatch has long troubled researchers seeking to translate laboratory findings into human therapies.

The research team, based in Germany, set out to close this gap with an unusually rigorous design. They compared young female C57BL/6 mice aged twelve to thirteen weeks with aged mice aged twenty to twenty-one months, inducing myocardial infarction by permanently ligating the left anterior descending coronary artery. Rather than relying on snapshots, they imaged each animal five days before surgery and again at two, seven, and twenty-eight days afterward, using a seven Tesla small-animal MRI system dedicated to cardiac imaging. This longitudinal cardiac magnetic resonance approach allowed them to track the same hearts over time, capturing end-diastolic and end-systolic volumes, stroke volume, ejection fraction, myocardial mass, and even deformation-based strain parameters with far greater precision than conventional echocardiography.

At baseline, the differences between the age groups were striking. Old mice had significantly larger ventricles and greater stroke volumes, reflecting their bigger bodies, while ejection fractions were similar across groups. Strain analysis—a technique that quantifies how much the heart muscle deforms during contraction—showed numerically higher values in young animals, hinting at greater contractile reserve, though the differences did not reach statistical significance. Statistical modeling confirmed that body weight, rather than age itself, largely explained the baseline differences in chamber volumes and myocardial mass, underscoring how easily confounded such comparisons can be when young and old animals differ so markedly in size.

After the infarction, both groups experienced the expected precipitous drop in ejection fraction within two days, and that impairment persisted through day twenty-eight. Here came the first surprise: young mice showed a steady, progressive decline in ejection fraction over the following weeks, whereas the aged animals’ function, though severely reduced, remained comparatively stable after the initial hit. Yet when the researchers compared the absolute trajectories between groups using linear mixed-effects models, they found no significant age-by-time interaction—meaning that, in raw terms, the two groups deteriorated along broadly similar paths.

The picture changed dramatically once the data were normalized to each animal’s own pre-infarction baseline. Because young mice started with ventricles roughly a third smaller than those of their aged counterparts, the same absolute increase in chamber volume represented a far greater proportional change. On this relative scale, both end-diastolic and end-systolic volumes showed significant effects of age, time, and—crucially—a significant age-by-time interaction, with young mice exhibiting significantly greater dilation at days seven and twenty-eight. Diastolic mass followed a similar pattern, rising about one-and-a-half-fold in young animals by day seven. In other words, the young hearts were not simply remodeling more in absolute terms; they were undergoing a fundamentally larger remodeling burden relative to their starting geometry.

Contractility data told a nuanced story. Feature-tracking strain analysis revealed profound deterioration in all strain parameters—global circumferential, longitudinal, and radial strain—in both groups after infarction, with significant time effects throughout. Only baseline-adjusted global longitudinal strain showed a statistically significant age-by-time interaction, suggesting that this single measure captured a genuinely different post-infarction trajectory between young and old hearts. The authors note that such strain-based metrics, which probe the quality of myocardial deformation rather than gross pumping performance, may be more sensitive indicators of age-dependent remodeling than ejection fraction alone.

Histology added an intriguing layer to the mystery. Scar size, quantified by Masson’s trichrome staining at days seven and twenty-eight, showed no significant differences between age groups, and immunostaining for type V collagen—a protein recently identified as a key regulator of scar maturation—revealed no age-dependent differences in its distribution. But the researchers did identify cell-free necrotic islands within the infarcted tissue, and these were smaller and less numerous in the young mice. This hints at a provocative possibility: young hearts may heal the structural defect faster, yet faster healing does not necessarily translate into better remodeling. Accelerated tissue repair and adverse geometric adaptation, the data suggest, are not the same thing.

The findings directly contradict several influential earlier studies. Work by Bujak and colleagues in 2008, using transient coronary occlusion and echocardiography, found worse dilation and function in aged mice, and Gould’s group had raised similar concerns two decades ago. The authors argue that methodological differences may explain much of the discordance: earlier studies used predominantly male mice, ketamine-xylazine anesthesia, M-mode echocardiography—which is poorly suited to the non-uniform remodeling that follows infarction—and varied infarct models. Notably, the new results align with a recent clinical report showing that younger STEMI patients, despite similar infarct characteristics, were actually more prone to adverse ventricular remodeling than older patients on follow-up cardiac MRI.

The study has limitations the authors acknowledge candidly: only female mice were studied, survival-related selection bias cannot be fully excluded, the permanent ligation model does not capture reperfusion injury as seen in modern clinical care, and the initial ischemic area was not directly measured. Still, the central message stands. This is the first mouse study to characterize age-dependent ventricular remodeling after infarction using longitudinal cardiac magnetic resonance, and it challenges the long-held assumption that aging necessarily amplifies post-infarction remodeling in this model. For a field built largely on twelve-week-old mice, the implication is uncomfortable but clarifying: comparable absolute changes can represent very different biological burdens depending on where the ventricle started, and the young heart’s apparent resilience deserves far more scrutiny than it has received.

Subject of Research: Age-dependent left ventricular remodeling after myocardial infarction in mice assessed by longitudinal cardiac magnetic resonance imaging

Article Title: Young Mice Exhibit Increased Relative Ventricular Remodeling After AMI—A Longitudinal CMR Study

Article References: Lemcke, H., Wörner, P., Dalmer, A., Gäbel, R., Vasudevan, P., Raitza, M., Schweins, M., Lindner, T., Ince, H., Krause, B. J., Vollmar, B., David, R., Meinel, F. G., & Lang, C. I. (2026). Young Mice Exhibit Increased Relative Ventricular Remodeling After AMI —A Longitudinal CMR Study. Aging Cell, 25(10), Article e70748. https://doi.org/10.1111/acel.70748

Image Credits: AI Generated

DOI: 10.1111/acel.70748

Keywords: myocardial infarction, ventricular remodeling, cardiac magnetic resonance, aging, mouse model, ejection fraction, strain analysis, scar formation, collagen type V, heart failure, C57BL/6 mice, cardiac regeneration

The research team, led by Javier Sanmartin and Roberto Elosua of the University of Vic-Central University of Catalonia, followed PRISMA guidelines and prospectively registered their protocol in PROSPERO. They searched PubMed, Scopus, and Web of Science from database inception through September 2023, with an updated search extending to June 2025. From 5,963 initially identified articles, the investigators retained 115 original studies after removing duplicates and screening titles, abstracts, and full texts. Risk of bias was assessed with the Joanna Briggs Institute Critical Appraisal Tool for Cross-Sectional Studies, and pooled estimates were generated using random-effects models with the Freeman-Tukey double arcsine transformation for proportions.

The headline number is 4 percent. Using the International-Seattle criteria, which define T-wave inversion as a negative T-wave of at least 1 millimeter in two contiguous leads, the pooled prevalence among athletes older than 16 years was 4 percent, with a 95 percent confidence interval of 3 to 6 percent. That figure, however, masks enormous variability: individual studies reported prevalences ranging from 0 to 42 percent, and the between-study heterogeneity, quantified by the I-squared statistic, exceeded 80 percent in most meta-analyses. The authors caution that the pooled estimate should be interpreted with this heterogeneity firmly in mind.

Location on the electrocardiogram matters enormously. Inversions were most common in the anterior leads V2 through V4, at roughly 3 percent, while inferior leads showed about 1 percent and lateral leads essentially 0 percent. This anatomical gradient carries clinical weight because lateral T-wave inversion is the pattern most frequently linked to confirmed structural heart disease. In the studies that evaluated cardiomyopathies among athletes with T-wave inversion, the most commonly identified conditions were hypertrophic cardiomyopathy, arrhythmogenic ventricular cardiomyopathy, and dilated cardiomyopathy, and lateral-lead inversions were disproportionately represented among those diagnosed.

Ethnicity emerged as a major modifier of prevalence. Black athletes showed an overall T-wave inversion rate of 13 percent, compared with 3 percent in Caucasian athletes, a difference consistent with known genetic, endocrine, and hemodynamic factors, including greater myocardial wall thickness and left ventricular mass. Notably, recent work cited in the review found that geographical origin within Africa also matters, with repolarisation abnormalities significantly more common among West African and Middle African athletes than among those from East or North Africa. Sex differences were smaller but present: women showed a slightly higher overall prevalence than men, 7 percent versus 5 percent, driven by anterior and inferior leads.

Perhaps the most striking comparative finding is that T-wave inversion is roughly 49 percent more common in athletes than in non-athletes. Across 14 studies that included control populations, the pooled prevalence ratio was 1.49, with a confidence interval of 1.13 to 1.97. The effect was strongest in the inferior leads, where the ratio reached 1.70. This supports the idea that intense training itself, through ventricular remodeling and autonomic changes, produces repolarisation patterns that would be considered abnormal in a sedentary person but are often physiological in an athlete.

The mechanisms behind these training-related inversions are diverse. The authors describe ventricular remodeling effects, including a high papillary muscle to left ventricular mass ratio and lateral displacement of the cardiac apex, which can explain anterior inversions. Structural variants such as left ventricular false tendons have also been implicated. Enhanced vagal tone in trained athletes activates acetylcholine-controlled potassium channels, reducing the action potential gradient between the epicardium and endocardium and altering the repolarisation vector. Myocardial ischemia, by contrast, can invert the repolarisation gradient in a pathological direction, which is one reason the finding cannot simply be dismissed.

Age adds another layer of nuance. In athletes aged 16 or younger, a juvenile T-wave inversion pattern in leads V1 through V3 is considered a normal variant, reflecting right ventricular dominance in early adolescence, and it generally regresses after age 16. The meta-analysis found this juvenile pattern in about 6 percent of young athletes. Interestingly, meta-regression identified age as the only variable that partially explained the heterogeneity between studies, with older athletes showing higher prevalence, a relationship the authors attribute to cumulative lifetime training volume.

On the critical prognostic question, the picture is murkier. Among 34 studies that assessed structural cardiomyopathies in athletes with T-wave inversion, most reported disease prevalence below 1 percent, though nine studies found rates between 1 and 10 percent and six exceeded 10 percent, likely reflecting deeper inversions, lateral predominance, referral-center recruitment, and more sensitive imaging such as cardiac magnetic resonance. Follow-up data were similarly heterogeneous: annual incidence rates of newly diagnosed cardiomyopathy ranged from 0 to 54.9 cases per 1,000 athletes, and major cardiovascular events ranged from 0 to 83.33 per 1,000 athlete-years. The authors attribute this wide spread to small samples, short follow-up, and selection biases, leaving the true event risk statistically uncertain.

The clinical message is a careful balance. T-wave inversion in athletes is more common than in the general population, most often involves the anterior leads, and frequently reflects benign exercise-induced remodeling, particularly in Black athletes and in younger age groups. Yet because it can also herald hypertrophic, arrhythmogenic, or dilated cardiomyopathy, especially when it appears in lateral leads or is accompanied by ST-segment depression, a thorough evaluation remains essential. The authors call for international, standardized, prospective studies with adequate sample sizes, uniform diagnostic protocols incorporating echocardiography, exercise testing, Holter monitoring, and cardiac magnetic resonance, and long-term follow-up to finally pin down which athletes with inverted T-waves truly need to worry.

Subject of Research: Prevalence and prognostic significance of T-wave inversions on electrocardiograms in athletes

Article Title: Frequency and Prognostic Significance of T-wave Inversions in Athletes: A Systematic Review and Meta-analysis

Article References: Sanmartin, J., Cartanya-Bonvehi, J., Valenzuela, H., Carballeira, L., Montserrat, S., Baranchuk, A., & Elosua, R. (2026). Frequency and Prognostic Significance of T-wave Inversions in Athletes: A Systematic Review and Meta-analysis. Sports Medicine – Open, 12(1), Article 147. https://doi.org/10.1186/s40798-026-01115-9

Image Credits: AI Generated

DOI: 10.1186/s40798-026-01115-9

Keywords: T-wave inversion, athletes, electrocardiogram, sudden cardiac death, cardiomyopathy, sports cardiology, meta-analysis, athlete's heart, ECG screening, ventricular remodeling, hypertrophic cardiomyopathy, prevalence

The patch itself is a small square studded with a 10 by 10 array of conical microneedles, each roughly 800 micrometers tall with a base diameter of about 300 micrometers. What makes the device remarkable is not its size but its internal architecture. Every needle is built in two concentric layers, fabricated through a stepwise centrifugal casting process into a silicone mold. The outer shell is made of methacrylated hyaluronic acid, or HAMA, a hydrophilic polymer that is photocrosslinked under 425-nanometer light. The inner core, along with the backing layer of the patch, is made of chitosan, a naturally occurring cationic polysaccharide. Each compartment carries a different therapeutic payload: the shell holds MCC950, a selective small-molecule inhibitor of the NLRP3 inflammasome, while the core carries basic fibroblast growth factor, or bFGF, a potent driver of blood vessel formation.

The choice of NLRP3 as the early target reflects a growing consensus about what goes wrong after a heart attack. When cardiomyocytes die from oxygen starvation, they release danger-associated molecular patterns that activate the NLRP3 inflammasome, a multiprotein immune sensor found in cardiomyocytes, fibroblasts, and infiltrating immune cells. Once assembled, this complex triggers caspase-1, which matures the inflammatory cytokines interleukin-1 beta and interleukin-18, amplifying cell death, fibrosis, and adverse ventricular remodeling. MCC950 works by blocking the oligomerization of ASC, the adaptor protein that assembles the inflammasome, and previous animal studies have shown it can shrink infarct size and preserve cardiac function. But timing is everything: NLRP3 activation peaks in the acute window, so delayed or systemic dosing risks missing the therapeutic moment while exposing the rest of the body unnecessarily.

The release kinetics engineered into the patch address that problem directly. Under acidic conditions mimicking the ischemic microenvironment, the MCC950 surrogate released about 23 percent of its payload within 15 minutes and 79 percent within one hour, with near-complete release by three days. That burst profile aligns precisely with the acute inflammatory phase. The bFGF story is entirely different: confined within the chitosan core, whose protonated amino groups bind the growth factor electrostatically, only 34.5 percent had escaped by day one, 50.2 percent by day four, and roughly 94 percent over 15 days. This sustained trickle is exactly what bFGF needs, since protein therapeutics degrade rapidly and vanish from tissue without a protective carrier. The researchers also found that release was faster at pH 5.4 than at physiological pH 7.4, suggesting the acidic infarct environment itself may help accelerate early drug delivery.

Mechanically, the patch proved robust enough for cardiac work. Compression testing showed the core-shell design withstood a maximum force of 30 newtons before complete insertion, thanks largely to the stiffness contributed by the crosslinked HAMA network. When a fluorescently labeled patch was pressed onto freshly excised rat left ventricular tissue, confocal imaging detected tracer deposited to a depth of approximately 700 micrometers, confirming that the needles physically penetrate the superficial myocardium rather than merely resting on its surface. That penetration matters therapeutically: it shortens the diffusion distance drugs must travel, improves local retention, and avoids the leakage and uneven distribution that plague direct intramyocardial injection, while keeping systemic exposure far lower than oral or intravenous routes would allow.

In laboratory dishes, the dual-loaded patch showed both faces of its therapeutic personality. When H9C2 rat cardiomyoblast cells were deprived of oxygen and glucose for eight hours, a condition that mimics ischemia, apoptosis climbed to 23.11 percent. Treatment with the MCC950-loaded patch cut that figure to 6.91 percent, and the dual-loaded version lowered it further to 6.03 percent. Molecular analysis confirmed the mechanism: levels of NLRP3, caspase-1, IL-1 beta, and IL-18 all dropped sharply in the MCC950-containing groups, while bFGF alone had little anti-inflammatory effect. On the vascular side, the story reversed. Human umbilical vein endothelial cells exposed to bFGF-containing patches proliferated vigorously, reaching nearly 180 percent viability at 72 hours, closed scratch wounds at rates of 94 to 96 percent within 24 hours, and formed dense capillary-like networks on Matrigel. Crucially, co-delivery of MCC950 did not blunt bFGF activity, and vice versa.

The decisive test came in rats subjected to permanent ligation of the left anterior descending coronary artery, a standard model of severe myocardial infarction. Patches were applied directly to the epicardial surface immediately after ligation, and the animals were followed for four weeks. Seven days after treatment, infarct tissue from rats receiving the dual-loaded patch showed markedly suppressed expression of NLRP3, IL-1 beta, and IL-18, and their serum levels of both cytokines were significantly reduced compared with untreated infarcted animals. Immunostaining revealed that NLRP3 suppression deepened between day 7 and day 28, while TUNEL staining showed apoptotic cell death falling steadily in the dual-treated group, evidence of a sustained protective effect rather than a transient pharmacological blip.

The functional outcomes were striking. By day 28, rats treated with the dual-loaded patch had a left ventricular ejection fraction of 69.4 percent and fractional shortening of 39.8 percent, compared with just 34.5 percent and 17.0 percent in untreated infarcted controls. Single-agent patches helped, but consistently less. End-diastolic and end-systolic volumes, which balloon as the ventricle dilates and remodels, were best preserved in the dual-treated group. Histology told the same story: hematoxylin and eosin staining showed better-preserved tissue architecture, Masson’s trichrome staining revealed the smallest fibrotic area of any treatment group, and ventricular wall thinning was markedly alleviated. Markers of angiogenesis, CD31 and alpha-SMA, were most strongly expressed in the dual-loaded group at day 28, indicating both new vessel formation and vascular maturation, while Ki67 staining pointed to a persistently active reparative microenvironment.

The authors are candid about the limitations that stand between this patch and the clinic. The in vitro release studies were conducted in static buffer conditions that cannot fully reproduce the dynamic pH, enzymatic activity, and interstitial flow of a living infarct, and the H9C2 cell line, being immature cardiomyoblasts, may not faithfully represent adult human cardiac inflammatory responses. The 28-day rat study leaves open questions about long-term biodegradation of the HAMA and chitosan matrix, potential residue persistence, and systemic biosafety. Perhaps most practically, the patch was implanted through open-chest surgery, a procedure that would need to be adapted to minimally invasive thoracoscopic or catheter-based delivery for real patients. Manufacturing reproducibility, sterilization, storage stability, and regulatory consistency also remain to be addressed.

Even so, the conceptual advance is considerable. Most biomaterial platforms for cardiac repair release their cargoes simultaneously or with little temporal distinction, ignoring the fact that infarct healing is a staged biological program in which the priorities of week one are nearly opposite to those of week four. By encoding a therapeutic sequence directly into material architecture, a fast-hydrating shell paired with a slow-releasing core, the researchers have demonstrated that drug presentation can be synchronized with disease-stage biology rather than fighting against it. The same logic, the authors note, could extend beyond cardiology to any condition marked by a transition from acute inflammation to regenerative remodeling, from diabetic wounds to spinal cord injury. For the millions of heart attack survivors who face progressive heart failure despite reperfusion therapy, a tiny two-layer needle array that knows which drug to release, and when, offers a glimpse of what precision biomaterial therapy might look like.

Subject of Research: A core-shell microneedle patch for sequential anti-inflammatory and pro-angiogenic drug delivery to repair heart tissue after myocardial infarction

Article Title: A core-shell microneedle patch coordinates early anti-inflammatory modulation and sustained pro-angiogenic stimulation for cardiac repair after myocardial infarction

Article References: A core-shell microneedle patch coordinates early anti-inflammatory modulation and sustained pro-angiogenic stimulation for cardiac repair after myocardial infarction. (n.d.). https://doi.org/10.1016/j.mtbio.2026.103704

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103704

Keywords: myocardial infarction, microneedle patch, NLRP3 inflammasome, MCC950, bFGF, angiogenesis, cardiac repair, drug delivery, hyaluronic acid, chitosan, ventricular remodeling, biomaterials

The central insight behind NGB is that the pathology of a heart attack is not static; it evolves through distinct phases, each demanding a different therapeutic response. In the earliest hours, injured heart muscle is ravaged by oxidative stress, inflammation, and a wave of programmed cell death driven by failing mitochondria. Later, if the patient survives that acute assault, the long-term story becomes one of metabolic maladaptation: the heart shifts abnormally toward glycolysis, accumulates toxic lipids, suffers acidosis, and loses the ability to generate ATP efficiently through oxidative phosphorylation. Most conventional treatments address only one moment in this timeline. NGB was designed, from the ground up, to span it.

Structurally, NGB is a co-assembled nanoparticle formed from nicotinamide adenine dinucleotide (NAD+), a universal cellular coenzyme essential for redox reactions and energy metabolism, and genipin, a natural plant-derived compound capable of inhibiting the mitochondrial uncoupling protein 2 (UCP2). The researchers first created a pre-crosslinked NAD+–genipin scaffold and then co-assembled it with free NAD+, producing particles whose surface displays clusters of pyridine rings from the NAD+ component. Molecular dynamics simulations revealed the network of hydrogen bonds and pi–pi stacking interactions that hold the structure together, and spectroscopic characterization confirmed the stability of the assembly under physiological conditions, with a gradual degradation profile extending across a full week in simulated bodily environments.

That degradation profile is the heart of the design. When NGB is injected intravenously after an induced heart attack in mice, it preferentially accumulates in the ischemic myocardium—a homing behavior the team verified by tracking fluorescently labeled particles as they concentrated in injured hearts within the first hour and persisted there for days. Once inside cells, the particles respond to the acidic environment of the damaged tissue by releasing an initial burst of free NAD+ within the first three hours. This rapid replenishment restores the NAD+/NADH ratio, buffering cells against the mitochondrial stress, intrinsic apoptosis, and inflammatory signaling that define the early injury phase. Then comes the second act: over the following hours and days, the remaining scaffold provides sustained, mitochondria-associated release of both NAD+ and genipin, maintaining therapeutic exposure precisely where the cell’s energy production takes place.

The temporal precision of this delivery was striking in the team’s measurements. In hypoxic cardiomyocytes treated with NGB, the NAD+/NADH ratio rose in three characteristic phases: a rapid early increase from zero to three hours, a pronounced elevation from three to twelve hours, and a sustained plateau from twelve to twenty-four hours. The same triphasic pattern appeared in the infarct and border regions of living hearts, and it outperformed nicotinamide mononucleotide, a popular NAD+ precursor that failed to achieve comparable sustained intracellular elevations. Docking studies further suggested that NGB particles associate with mitochondrial outer membrane proteins, including the translocase complex TOM and the voltage-dependent anion channel VDAC, positioning the sustained-release depot directly at the doorstep of the mitochondria.

To understand how this staged therapy reshapes cardiac metabolism, the researchers turned to transcriptomics and metabolomics. RNA sequencing of treated hearts revealed a broad restoration of genes governing oxidative metabolism, while metabolomic profiling showed normalized ratios of glycolysis- and acidosis-related metabolites, energy nucleotides, purine intermediates, and medium- and long-chain fatty acids. In essence, NGB appeared to pull the post-infarct heart back from its maladaptive metabolic rewiring—correcting the HIF-1α-driven shift toward anaerobic glycolysis, restraining lactic acid buildup, and re-coordinating the interplay between glucose utilization, fatty-acid beta-oxidation, and mitochondrial respiration.

The mechanistic core of the story lies in two molecular players: sirtuin 1 (SIRT1) and uncoupling protein 2 (UCP2). SIRT1, an NAD+-dependent deacetylase, activates PGC-1α and PPARα, master regulators of mitochondrial oxidative metabolism. By sustaining NAD+ availability, NGB keeps this SIRT1–PGC-1α axis engaged, supporting the heart’s capacity to burn fuel efficiently. UCP2, by contrast, emerged as a pathological culprit: after infarction, its expression climbed persistently, uncoupling oxidative phosphorylation and wasting energy while promoting lipotoxic accumulation. Genipin, delivered in the second therapeutic phase, suppressed this sustained UCP2 upregulation. The team confirmed causality through gain- and loss-of-function experiments: knocking down UCP2 in hypoxic cardiomyocytes and supplementing NAD+ partially reproduced the NGB metabolic phenotype, whereas overexpressing UCP2 or inhibiting SIRT1 reversed distinct components of the respiratory and glycolytic recovery the nanomedicine enables.

Downstream, the consequences cascaded favorably across the injured heart. NGB treatment limited the release of cytochrome c and the intrinsic apoptotic cascade, reduced mitochondrial DNA leakage that would otherwise fuel chronic cGAS–STING-mediated inflammation, and attenuated the fibrotic scarring and ventricular remodeling that convert a single infarct into progressive heart failure. Echocardiography over twenty-eight days showed preserved left ventricular ejection fraction and fractional shortening in treated animals compared with untreated infarct controls, with histological staining revealing thicker infarct walls and smaller fibrotic regions. Dose-optimization studies identified an effective intravenous range, and delayed-treatment experiments confirmed that even later administration retained meaningful benefit. Toxicology screens—spanning blood counts, liver and kidney function markers, and histology of major organs—showed no apparent adverse effects at therapeutic doses.

The broader significance of this work extends beyond a single molecule. NGB exemplifies an emerging philosophy in nanomedicine: that complex, evolving diseases demand therapies whose release kinetics are matched to the temporal structure of the pathology itself. Rather than flooding the body with a static dose of NAD+ or a blunt metabolic drug, the Changsha team engineered a delivery system that behaves almost physiologically—responding to the acidic, damaged microenvironment, homing to the infarct, and staging its intervention in phase with the heart’s own deteriorating and then recovering metabolism. While the findings remain at the preclinical stage in rodents, and translation to human patients will require extensive further testing, the study offers a compelling blueprint for temporally coordinated metabolic intervention after myocardial infarction. For a condition that remains a leading cause of death and long-term disability worldwide, a therapy that not only rescues heart muscle in its darkest hour but also guides its metabolic recovery over the weeks that follow represents a genuinely exciting direction for cardiovascular medicine.

Subject of Research: A bioadaptive NAD+–genipin nanomedicine that delivers staged metabolic therapy to restore mitochondrial function and cardiac performance after myocardial infarction.

Article Title: Bioadaptive spatiotemporal nanomedicine promotes metabolic recovery after myocardial infarction through NAD+ and UCP2 regulation

Article References: Wang, J., Xia, Y., Zheng, W., Yuan, W., Huang, Y., Zhang, Y., Huang, Q., & Ai, K. (2026). Bioadaptive spatiotemporal nanomedicine promotes metabolic recovery after myocardial infarction through NAD+ and UCP2 regulation. Nature Cardiovascular Research. https://doi.org/10.1038/s44161-026-00874-8

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00874-8

Keywords: myocardial infarction, nanomedicine, NAD+, UCP2, mitochondria, SIRT1, cardiac metabolism, ventricular remodeling, genipin, heart failure, oxidative phosphorylation, glycolysis